Lushang Freda Pharmaceutical Co.,Ltd. (SHA:600223)
China · Delayed Price · Currency is CNY 6.77
-0.21 (-3.01%)
Apr 3, 2026, 3:00 PM CST
SHA:600223 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,651 | 3,944 | 4,511 | 12,659 | 12,201 |
Other Revenue | - | 38.9 | 67.66 | 292.87 | 161.85 |
| 3,651 | 3,983 | 4,579 | 12,951 | 12,363 | |
Revenue Growth (YoY) | -8.33% | -13.02% | -64.65% | 4.76% | -9.20% |
Cost of Revenue | 1,725 | 1,891 | 2,457 | 10,025 | 9,384 |
Gross Profit | 1,926 | 2,091 | 2,121 | 2,926 | 2,980 |
Selling, General & Admin | 1,546 | 1,644 | 1,668 | 1,661 | 1,628 |
Research & Development | 161.72 | 166.77 | 153.36 | 133.92 | 118.75 |
Other Operating Expenses | 9.82 | 40.15 | 36.42 | 539.39 | 585.63 |
Operating Expenses | 1,718 | 1,877 | 1,894 | 2,350 | 2,343 |
Operating Income | 208.2 | 214.71 | 227.71 | 575.66 | 636.91 |
Interest Expense | - | -22.12 | -94.75 | -400.97 | -112.32 |
Interest & Investment Income | 55.39 | 115.8 | 259.29 | 163.61 | 239.56 |
Currency Exchange Gain (Loss) | - | 1.85 | 0.32 | 12.59 | -1.14 |
Other Non Operating Income (Expenses) | 31.21 | -1.7 | -8 | -62.17 | -139.2 |
EBT Excluding Unusual Items | 294.8 | 308.55 | 384.56 | 288.73 | 623.82 |
Impairment of Goodwill | - | - | -1.85 | -4.74 | -3.98 |
Gain (Loss) on Sale of Assets | -0.06 | 0.42 | -1.12 | 0.44 | -0.04 |
Asset Writedown | -9.87 | - | - | - | - |
Other Unusual Items | - | 37.33 | 31.37 | -23.37 | 23.93 |
Pretax Income | 284.88 | 346.29 | 412.96 | 261.06 | 643.73 |
Income Tax Expense | 47.39 | 49.85 | 46.82 | 195.96 | 249.93 |
Earnings From Continuing Operations | 237.48 | 296.44 | 366.14 | 65.1 | 393.8 |
Minority Interest in Earnings | -49.73 | -52.92 | -62.75 | -19.64 | -31.9 |
Net Income | 187.75 | 243.53 | 303.39 | 45.46 | 361.9 |
Net Income to Common | 187.75 | 243.53 | 303.39 | 45.46 | 361.9 |
Net Income Growth | -22.90% | -19.73% | 567.44% | -87.44% | -43.34% |
Shares Outstanding (Basic) | 1,043 | 1,015 | 1,011 | 1,136 | 1,005 |
Shares Outstanding (Diluted) | 1,043 | 1,015 | 1,011 | 1,136 | 1,034 |
Shares Change (YoY) | 2.80% | 0.34% | -11.01% | 9.90% | 2.00% |
EPS (Basic) | 0.18 | 0.24 | 0.30 | 0.04 | 0.36 |
EPS (Diluted) | 0.18 | 0.24 | 0.30 | 0.04 | 0.35 |
EPS Growth | -25.00% | -20.00% | 650.00% | -88.57% | -44.44% |
Free Cash Flow | 165.8 | 71.44 | 262.79 | 831.98 | 6,567 |
Free Cash Flow Per Share | 0.16 | 0.07 | 0.26 | 0.73 | 6.35 |
Dividend Per Share | - | 0.110 | 0.100 | 0.110 | 0.110 |
Dividend Growth | - | 10.00% | -9.09% | - | -45.00% |
Gross Margin | 52.76% | 52.51% | 46.33% | 22.59% | 24.10% |
Operating Margin | 5.70% | 5.39% | 4.97% | 4.45% | 5.15% |
Profit Margin | 5.14% | 6.12% | 6.63% | 0.35% | 2.93% |
Free Cash Flow Margin | 4.54% | 1.79% | 5.74% | 6.42% | 53.12% |
EBITDA | 311.14 | 308.37 | 363.55 | 692.15 | 729.53 |
EBITDA Margin | 8.52% | 7.74% | 7.94% | 5.34% | 5.90% |
D&A For EBITDA | 102.94 | 93.66 | 135.84 | 116.49 | 92.62 |
EBIT | 208.2 | 214.71 | 227.71 | 575.66 | 636.91 |
EBIT Margin | 5.70% | 5.39% | 4.97% | 4.45% | 5.15% |
Effective Tax Rate | 16.64% | 14.40% | 11.34% | 75.06% | 38.83% |
Revenue as Reported | - | 3,983 | 4,579 | 12,951 | 12,363 |
Advertising Expenses | - | 811.13 | 784.1 | 705.36 | 630.15 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.